Spectrum Pharma Inc (SPPI) 7.05 $SPPI Spectrum

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Spectrum Pharma Inc (SPPI) 7.05 $SPPI

Spectrum Pharmaceuticals Shares Up 28.1% Since SmarTrend's Buy Recommendation (SPPI)
Comtex SmarTrend(R) - Fri Jul 29, 1:27PM CDT
SmarTrend identified an Uptrend for Spectrum Pharmaceuticals (NASDAQ:SPPI) on March 10th, 2016 at $5.34. In approximately 5 months, Spectrum Pharmaceuticals has returned 28.09% as of today's recent price of $6.84.
SPPI: 7.05 (+0.18)

Watch for Spectrum Pharmaceuticals to Potentially Rebound After Falling 1.71% Yesterday
Comtex SmarTrend(R) - Wed Jul 13, 4:44PM CDT
Spectrum Pharmaceuticals (NASDAQ:SPPI) traded in a range yesterday that spanned from a low of $6.62 to a high of $6.78. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $6.69 on volume of 246,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
SPPI: 7.05 (+0.18)

Biotechnology Stocks Under the Scanner -- PTC Therapeutics, Inovio Pharma, VIVUS, and Spectrum Pharma
PR Newswire - Mon Jul 11, 7:23AM CDT
On Friday, July 08, 2016, the NASDAQ Composite ended the trading session at 4,956.76, up 1.64%; the Dow Jones Industrial Average advanced 1.40%, to finish at 18,146.74; and the S&P 500 closed at 2,129.90, up 1.53%. The gains were broad based as all the sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: PTC Therapeutics Inc. (NASDAQ: PTCT), Inovio Pharmaceuticals Inc. (NASDAQ: INO), VIVUS Inc. (NASDAQ: VVUS), and Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI). Learn more about these stocks by accessing their free notes at:
INO: 10.42 (+0.54), VVUS: 1.05 (-0.02), PTCT: 6.10 (+0.13), SPPI: 7.05 (+0.18)

Spectrum Pharmaceuticals Has Returned 27.2% Since SmarTrend Recommendation (SPPI)
Comtex SmarTrend(R) - Thu Jul 07, 12:41AM CDT
SmarTrend identified an Uptrend for Spectrum Pharmaceuticals (NASDAQ:SPPI) on March 10th, 2016 at $5.34. In approximately 4 months, Spectrum Pharmaceuticals has returned 27.15% as of today's recent price of $6.79.
SPPI: 7.05 (+0.18)

Uptrend Call Working As Spectrum Pharmaceuticals Stock Rises 26.0% (SPPI)
Comtex SmarTrend(R) - Tue Jun 21, 1:34PM CDT
SmarTrend identified an Uptrend for Spectrum Pharmaceuticals (NASDAQ:SPPI) on March 10th, 2016 at $5.34. In approximately 3 months, Spectrum Pharmaceuticals has returned 26.03% as of today's recent price of $6.73.
SPPI: 7.05 (+0.18)

Spectrum Pharmaceuticals Up 28.7% Since SmarTrend Uptrend Call (SPPI)
Comtex SmarTrend(R) - Tue Jun 14, 12:59AM CDT
SmarTrend identified an Uptrend for Spectrum Pharmaceuticals (NASDAQ:SPPI) on March 10th, 2016 at $5.34. In approximately 3 months, Spectrum Pharmaceuticals has returned 28.65% as of today's recent price of $6.87.
SPPI: 7.05 (+0.18)

Spectrum Pharmaceuticals Up 35.6% Since SmarTrend Uptrend Call (SPPI)
Comtex SmarTrend(R) - Mon Jun 06, 1:27PM CDT
SmarTrend identified an Uptrend for Spectrum Pharmaceuticals (NASDAQ:SPPI) on March 10th, 2016 at $5.34. In approximately 3 months, Spectrum Pharmaceuticals has returned 35.58% as of today's recent price of $7.24.
SPPI: 7.05 (+0.18)

Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2016 Healthcare Conference on June 8th
BusinessWire - Wed Jun 01, 6:00AM CDT
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the Company's business strategy and commercial and development-stage programs will be given at the Jefferies 2016 Healthcare Conference being held at the Grand Hyatt in New York. The Company presentation is on Wednesday, June 8, 2016, at 10:30 AM ET.
SPPI: 7.05 (+0.18)

Uptrend Call Working As Spectrum Pharmaceuticals Stock Rises 39.1% (SPPI)
Comtex SmarTrend(R) - Fri May 27, 1:06PM CDT
SmarTrend identified an Uptrend for Spectrum Pharmaceuticals (NASDAQ:SPPI) on March 10th, 2016 at $5.34. In approximately 3 months, Spectrum Pharmaceuticals has returned 39.14% as of today's recent price of $7.43.
SPPI: 7.05 (+0.18)

Spectrum Pharmaceuticals Shares Up 33.0% Since SmarTrend's Buy Recommendation (SPPI)
Comtex SmarTrend(R) - Thu May 12, 1:09PM CDT
SmarTrend identified an Uptrend for Spectrum Pharmaceuticals (NASDAQ:SPPI) on March 10th, 2016 at $5.34. In approximately 2 months, Spectrum Pharmaceuticals has returned 32.96% as of today's recent price of $7.10.
SPPI: 7.05 (+0.18)

Spectrum Pharma reports 1Q loss
Automated Insights - Thu May 05, 3:25PM CDT
HENDERSON, Nev. (AP) _ Spectrum Pharmaceuticals Inc. (SPPI) on Thursday reported a loss of $9.3 million in its first quarter.
SPPI: 7.05 (+0.18)

Spectrum Pharmaceuticals Reports First Quarter 2016 Financial Results and Pipeline Update
BusinessWire - Thu May 05, 3:00PM CDT
--Poziotinib, a novel pan-HER inhibitor: A Phase 2 trial was initiated and is enrolling breast cancer patients who have failed other HER2-directed therapies.
SPPI: 7.05 (+0.18)

30.3% Return Seen to Date on SmarTrend Spectrum Pharmaceuticals Call (SPPI)
Comtex SmarTrend(R) - Thu May 05, 12:49AM CDT
SmarTrend identified an Uptrend for Spectrum Pharmaceuticals (NASDAQ:SPPI) on March 10th, 2016 at $5.34. In approximately 2 months, Spectrum Pharmaceuticals has returned 30.34% as of today's recent price of $6.96.
SPPI: 7.05 (+0.18)

Ligand (LGND) Q1 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Mon May 02, 10:09AM CDT
Will Ligand (LGND) pull a surprise and surpass expectations in the first quarter as well?
LGND: 138.53 (+3.65), SPPI: 7.05 (+0.18), BIND: 0.78 (-0.09), FOLD: 6.71 (-0.01)

FDA Grants Orphan Drug Exclusivity to EVOMELA(TM) (melphalan) for Injection, Indicated for Multiple Myeloma
BusinessWire - Wed Apr 20, 6:00AM CDT
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced today that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) has granted 7 years of Orphan Drug Exclusivity for EVOMELA for use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma. EVOMELA has also been recently listed in the Orange Book, including two composition of matter patents that do not expire until March 2029.
SPPI: 7.05 (+0.18)

Four Biotech Stocks To Consider As The Sector Breaks Out
ACCESSWIRE - Thu Apr 07, 11:57AM CDT
NEW YORK, NY / ACCESSWIRE / April 7, 2016 / Has biotech finally bottomed? After an 8-month long bear market with biotech stocks losing over 40%, signs of a breakout are now becoming more and more obvious. All eyes are on the iShares NASDAQ Biotechnology Index ETF (NASDAQ:IBB) as the 50 day moving average has been overtaken since the beginning of the month.
VRX: 20.89 (-1.41), CRBP: 2.80 (+0.03), DMPI: 7.02 (+0.44), IBB: 294.07 (+4.63), SPPI: 7.05 (+0.18)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Why Lear’s PACE Award Matters Beyond Seat Warmers Today

Updated Category News Views 111

Seat foam and wiring seldom make investors sit upright, yet Lear has managed to turn that unglamorous corner of the vehicle into something worth watching. The company’s Modular Thermal Comfort Systems just won a 2026 Automotive News PACE Award, a respected supplier-industry nod for innovation and business performance. Awards alone do not pay anybody’s bills, and I...

Continue Reading
Layne’s Jacksonville Debut Tests East Texas Expansion

Updated Category News Views 95

Jacksonville is not some flashy coastal launch, and that is precisely why this Layne’s Chicken Fingers opening matters. A new chicken tender shop at 1217 S. Jackson St. will not move public markets, because this is a franchise-growth story rather than a ticker story. But it does offer a clean look at whether Layne’s can turn its Texas roots into a durable multi-market...

Continue Reading
Roof Leaks Demand Diagnosis Before the Repair Bill

Updated Category News Views 95

A brown ring on a ceiling is often the last witness, not the crime scene. That is the useful, unglamorous point in Jonathan Floyd's HelloNation discussion of roof leaks: water has plenty of ways to move after it slips past a roof's defenses. Homeowners understandably stare at the stain and assume the answer sits directly overhead. Sometimes it does. Plenty of times, it...

Continue Reading
Sinopec's Green Fuel Push Meets a Hard Reality Check

Updated Category News Views 104

A refinery giant talking about green jet fuel at a climate summit is exactly the sort of thing that makes old energy hands squint first—and then check the asset list. Sinopec did bring more than lofty language to its Nov. 16 COP31 side event in Antalya: it brought long-range energy forecasts, named fuel-production routes, hydrogen infrastructure and operating projects....

Continue Reading
Wallstreet Sand Hands Its Massive Permian Plant to Wilbanks

Updated Category News Views 210

A sand plant can brag about acreage and horsepower all day, but frac crews remember who kept material arriving when a completion schedule got ugly. That is the real backdrop to PI Holdings and Wallstreet Sand Co. naming Blaine Wilbanks president of both businesses on November 18, 2026. This is not a ceremonial chair swap. Wallstreet has built an enormous Permian sand...

Continue Reading
MIND Takes Its Copilot Security Bet Across Microsoft 365

Updated Category News Views 92

Copilot’s promise gets a lot less charming the minute confidential files start wandering around unchecked. That is the knot MIND is trying to untie with its expanded, generally available integrations across Microsoft Copilot, Microsoft 365, Purview, Teams, SharePoint, OneDrive, Edge and Exchange. The Seattle data-loss-prevention company announced the collaboration on...

Continue Reading
Condo Downsizing Demands More Than a Price Check Today

Updated Category News Views 58

A smaller front door can hide a surprisingly large stack of obligations. That is the useful point in the HelloNation guidance featuring Chevy Chase real estate expert Lise Howe: downsizing into a condo is not merely a square-footage trade. It is a decision about recurring costs, building stewardship, daily friction, and whether the place still works when life gets less...

Continue Reading
BVM's Brookfield Headquarters Move Tests Growth Ambition

Updated Category News Views 152

A bigger office is rarely the exciting part of a growth story, yet it can reveal whether the machinery underneath is actually running hot. Best Version Media has moved its headquarters from Janacek Court to 15800 W. Bluemound Road, Suite 400, in Brookfield, Wisconsin, citing room for recent hires, future recruitment and closer collaboration across its print and digital...

Continue Reading
Vector Adds Mesa Division 10 Veteran for Arizona Growth

Updated Category News Views 135

A toilet-partition deal rarely raises eyebrows, but this one has the sturdy logic investors ought to notice. Vector Building Products has acquired Mesa-based Partitions & Accessories Co., a Division 10 specialist that has served Arizona contractors since 1978. It is not glamorous work. It is, however, the sort of necessary, specification-driven business that gets embedded...

Continue Reading
Zoomcar's November 23 Report Puts Execution on Trial

Updated Category News Views 55

A Date on the Board, Not a Verdict November 23 is when Zoomcar finally has to put some fresh numbers beside the story. The Bengaluru-based peer-to-peer car-sharing marketplace says it will release second-quarter fiscal 2027 financial and operating results that Monday, covering the quarter ended September 30, 2026. Management also plans a live webcast at 8:00 a.m. Eastern...

Continue Reading

Top 5 Most Recently Viewed Articles

Main Street Capital Reports Impressive Q2 2025 Financials

Updated Category News Views 326

Main Street's Second Quarter 2025 Financial Performance Main Street Capital Corporation (NYSE: MAIN) recently disclosed its remarkable financial results for the second quarter of 2025. The company reported a net investment income of $88.2 million, which translates to approximately $0.99 per share. Additionally, the distributable net investment income stood at $94.3...

Continue Reading
argenx's Q1 2025 Growth: VYVGART Performance Shines Brightly

Updated Category News Views 463

Q1 2025 Financial Results Unveiled by argenx argenx SE, listed on both Nasdaq and Euronext as ARGX, is making waves in the biotech industry with its recent announcement of first-quarter financial results and a comprehensive business update. CEO Tim Van Hauwermeiren expressed enthusiasm regarding the company's trajectory, focusing on their ambitious "Vision 2030"—a...

Continue Reading
Pennsylvania's Resilient Housing Market: An Overview of Trends

Updated Category News Views 135

Pennsylvania Housing Market Shows Notable Resilience The latest data on the housing market in Pennsylvania highlights an encouraging trend, as home prices have experienced a remarkable increase of 6.5% over the past year. This consistent appreciation indicates a vigorous market, even in the face of fluctuating economic conditions. Median Home Prices Reach New Heights In...

Continue Reading
Yum China's Strategy Bolstered by Pizza Hut Buy

Updated Category News Views 129

Yum China's Bold Step Forward Here's a twist in the fast-food market worth chewing on: Yum China has wrapped up its $1.2 billion acquisition of the Pizza Hut brand in Mainland China from Yum! Brands. It's like snagging the keys to a long-coveted car after being the chauffeur for decades. Strategic Flexibility and Margin Growth What's at play? Well, Joey Wat, CEO of Yum...

Continue Reading
Insightful Overview of NCC Group plc's Recent Trading Activity

Updated Category News Views 88

Understanding Recent Trading Activities of NCC Group plc In the fast-paced world of finance, keeping an eye on trading activities can offer invaluable insights. One company that has recently been under the spotlight is NCC Group plc. The trading revelations come from public disclosures made under Rule 8.5, indicating vital movements in their securities. Key Information...

Continue Reading